QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

SAN DIEGO & HILDEN, Germany & GERMAN TOWN, Md.--(BUSINESS WIRE)-- #DNAprofiling--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and Verogen Inc. today announced a partnership to provide laboratories with superior tools and comprehensive support for implementing next-generation sequencing (NGS) human identification workflows. The partnership with QIAGEN is a milestone-driven distribution and development agreement that grants QIAGEN rights to globally distribute both current and future Verogen products

Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #forensics--QIAGEN partners with Verogen to offer broadest portfolio for human identification, including next generation sequencing solutions

QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions

Cleveland-Cliffs

Dine Brands Global

Freeport-McMoRan

Kinross Gold

Landbridge Co LLC

Plains All American Pipeline

Rent-A-Center

Sirius XM Holdings Inc

Molson Coors Brewing

Growth at a reasonable price (GARP) stocks are investing's version of having your cake and eating it too.

11 Great GARP Stocks to Buy Now

Qiagen NV (NYSE: QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function. QiaPrep&Amp CRISPR Kit and Q-Primer Solutions expand Qiagen portfolio for CRISPR applications.

Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments

HILDEN, Germany, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #CRISPR--QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments

QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Qiagen (QGEN) Down 0.7% Since Last Earnings Report?

QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.

QIAGEN (QGEN) Launches Expanded Tissue CDx Kit for LUMAKRAS

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #fda--QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours

QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer

QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.

QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #CDx--QIAGEN partners with Mirati Therapeutics Inc. to develop KRAS(G12C) companion diagnostic for non-small cell lung cancer (NSCLC)

QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)

QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.

QIAGEN (QGEN) Gains from FDA's EUA for Antibody Total Test

VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces creation of Scientific Advisory Board and agenda for Annual General Meeting in June 2021

QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021

QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.

QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN receives U.S. FDA Emergency Use Authorization for fast and easy-to-use digital test to detect SARS-CoV-2 coronavirus antibodies

QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies

QIAGEN's (QGEN) CEO Thierry Bernard on Q1 2021 Results - Earnings Call Transcript

QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.

QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up

Qiagen NV (NYSE: QGEN) on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst consensus by $9.68 million. Adjusted EPS $0.65 beat analyst consensus of $0.63 and exceeded prior company guidance of $0.60 - $0.62.

Qiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost Revenues

U.S.-German genetic testing specialist Qiagen reported slightly better-than-expected quarterly earnings on Monday as sales growth for non-coronavirus products added to high demand for its COVID-19 testing solutions.

Qiagen reports first-quarter beat thanks to growth in non-COVID-19 products

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #earnings--QIAGEN exceeds outlook in first quarter 2021 results, reaffirms sales growth and profitability outlook for full-year 2021

QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces EZ2 Connect instrument line for automated sample processing in research, forensics and diagnostics

QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics

HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN with DiaSorin, announce the launch of LIAISON® LymeDetect® Assay based on QuantiFERON technology for early diagnosis of Lyme Borreliosis

QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN launches artus Prep&Amp as CE-marked SARS-CoV-2 test offering up to threefold increase in daily lab testing capacity

QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report First Quarter 2021 Results

QIAGEN N.V. to Report First Quarter 2021 Results

Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

Bio-Techne

QGEN vs. TECH: Which Stock Is the Better Value Option?

News for QIAGEN Stock (QGEN)